359 research outputs found
Type-II InAs/GaAsSb Quantum Dot Solar Cells With GaAs Interlayer
One of the primary challenges facing quantum dot (QD)-based intermediate band solar cells is the short lifetime of charge carriers (∼1 ns). To investigate this, InAs QD/GaAs 1--xSbx quantum well (QW) solar cells (SCs) with a 2-nm GaAs interlayer between the QDs and QW were fabricated for x = 0, 0.08, 0.14, and 0.17, respectively. Time-resolved photoluminescence measurements demonstrated prolonged carrier lifetimes up to 480 ns for the type-II SCs with x ≥ 14%. This improvement in carrier lifetime is assigned to the GaAs interlayer that reduces the wavefunction overlap between the electrons accumulated in the QDs and holes in the QW, and hence limits the possible emission pathways. External quantum efficiency measurements were performed to analyze the SC performance. An order of magnitude improvement was observed in the QD region (900–1200 nm) for the type-II SCs and is linked to the prolonged carrier lifetime
Radioimmunotherapy for mantle cell lymphoma : 5-year follow-up of 90 patients from the international RIT registry
To assess the efficacy of radioimmunotherapy (RIT) wit
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Ibrutinib, an oral inhibitor of Bruton tyrosine kinase, is approved for patients with mantle cell lymphoma (MCL) who have received one prior therapy. We report the updated safety and efficacy results from the multicenter, open-label phase 2 registration trial of Ibrutinib (median 26.7-month follow-up). Patients (N = 111) received oral ibrutinib 560 mg once daily, and those with stable disease or better could enter a long-term extension study. The primary end point was overall response rate (ORR). The median patient age was 68 years (range, 40-84), with a median of 3 prior therapies (range, 1-5). The median treatment duration was 8.3 months; 46% of patients were treated for \u3e12 months, and 22% were treated for \u3e= 2 years. The ORR was 67% (23% complete response), with a median duration of response of 17.5 months. The 24-month progression-free survival and overall survival rates were 31% (95% confidence interval [Cl], 22.3-40.4) and 47% (95% Cl, 37.1-56.9), respectively. The most common adverse events (AEs) in \u3e30% of patients included diarrhea (54%), fatigue (50%), nausea (33%), and dyspnea (32%). The most frequent grade \u3e= 3 infections included pneumonia (8%), urinary tract infection (4%), and cell ulitis (3%). Grade bleeding events in \u3e= 2% of patients were hematuria (2%) and subdural hematoma (2%). Common all-grade hematologic AEs were thrombocytopenia (22%), neutropenia (19%), and anemia (18%). The prevalence of infection, diarrhea, and bleeding was highest for the first 6 months of therapy and less thereafter. With longer follow-up, ibrutinib continues to demonstrate durable responses and favorable safety in relapsed/refractory MCL. The trial is registered to www.ClinicalTrials.gov as #NCT01236391
Reversal of Hypertriglyceridemia, Fatty Liver Disease, and Insulin Resistance by a Liver-Targeted Mitochondrial Uncoupler
SummaryNonalcoholic fatty liver disease (NAFLD) affects one in three Americans and is a major predisposing condition for the metabolic syndrome and type 2 diabetes (T2D). We examined whether a functionally liver-targeted derivative of 2,4-dinitrophenol (DNP), DNP-methyl ether (DNPME), could safely decrease hypertriglyceridemia, NAFLD, and insulin resistance without systemic toxicities. Treatment with DNPME reversed hypertriglyceridemia, fatty liver, and whole-body insulin resistance in high-fat-fed rats and decreased hyperglycemia in a rat model of T2D with a wide therapeutic index. The reversal of liver and muscle insulin resistance was associated with reductions in tissue diacylglycerol content and reductions in protein kinase C epsilon (PKCε) and PKCθ activity in liver and muscle, respectively. These results demonstrate that the beneficial effects of DNP on hypertriglyceridemia, fatty liver, and insulin resistance can be dissociated from systemic toxicities and suggest the potential utility of liver-targeted mitochondrial uncoupling agents for the treatment of hypertriglyceridemia, NAFLD, metabolic syndrome, and T2D
Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6
Ibrutinib may inhibitintestinal CYP3A4 and induce CYP2B6 and/or CYP3A. Secondary
to potential induction, ibrutinib may reduce the exposure and effectiveness of oral
contraceptives (OCs). This phase I study evaluated the effect of ibrutinib on the pharmacokinetics of the CYP2B6 substrate bupropion, CYP3A substrate midazolam, and
OCs ethinylestradiol (EE) and levonorgestrel (LN). Female patients (N = 22) with B-cell
malignancies received single doses of EE/LN (30/150 μg) and bupropion/midazolam
(75/2 mg) during a pretreatment phase on days 1 and 3, respectively (before starting ibrutinib on day 8), and again after ibrutinib 560 mg/day for ≥ 2 weeks. Intestinal
CYP3A inhibition was assessed on day 8 (single-dose ibrutinib plus single-dose midazolam). Systemic induction was assessed at steady-state on days 22 (EE/LN plus ibrutinib) and 24 (bupropion/midazolam plus ibrutinib). The geometric mean ratios (GMRs;
test/reference) for maximum plasma concentration (Cmax) and area under the plasma
concentration-time curve (AUC) were derived using linear mixed-effects models (90%
confidence interval within 80%-125% indicated no interaction). On day 8, the GMR
for midazolam exposure with ibrutinib coadministration was ≤ 20% lower than the reference, indicating lack of intestinal CYP3A4 inhibition. At ibrutinib steady-state, the
Cmax and AUC of EE were 33% higher than the reference, which was not considered
clinically relevant. No substantial changes were noted for LN, midazolam, or bupropion. No unexpected safety findings were observed. A single dose of ibrutinib did not
inhibit intestinal CYP3A4, and repeated administration did not induce CYP3A4/2B6,
as assessed using EE, LN, midazolam, and bupropion
Synchronization of Hamiltonian motion and dissipative effects in optical lattices: Evidence for a stochastic resonance
We theoretically study the influence of the noise strength on the excitation
of the Brillouin propagation modes in a dissipative optical lattice. We show
that the excitation has a resonant behavior for a specific amount of noise
corresponding to the precise synchronization of the Hamiltonian motion on the
optical potential surfaces and the dissipative effects associated with optical
pumping in the lattice. This corresponds to the phenomenon of stochastic
resonance. Our results are obtained by numerical simulations and correspond to
the analysis of microscopic quantities (atomic spatial distributions) as well
as macroscopic quantities (enhancement of spatial diffusion and pump-probe
spectra). We also present a simple analytical model in excellent agreement with
the simulations
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
In the mantle cell lymphoma (MCL)-002 study, lenalidomide demonstrated significantly improved median progression-free survival (PFS) compared with investigator's choice (IC) in patients with relapsed/refractory MCL. Here we present the long-term follow-up data and results of preplanned subgroup exploratory analyses from MCL-002 to evaluate the potential impact of demographic factors, baseline clinical characteristics and prior therapies on PFS. In MCL-002, patients with relapsed/refractory MCL were randomized 2:1 to receive lenalidomide (25 mg/day orally on days 1-21; 28-day cycles) or single-agent IC therapy (rituximab, gemcitabine, fludarabine, chlorambucil or cytarabine). The intent-to-treat population comprised 254 patients (lenalidomide, n = 170; IC, n = 84). Subgroup analyses of PFS favoured lenalidomide over IC across most characteristics, including risk factors, such as high MCL International Prognostic Index score, age ≥65 years, high lactate dehydrogenase (LDH), stage III/IV disease, high tumour burden, and refractoriness to last prior therapy. By multivariate Cox regression analysis, factors associated with significantly longer PFS (other than lenalidomide treatment) included normal LDH levels (P < 0·001), nonbulky disease (P = 0·045), <3 prior antilymphoma treatments (P = 0·005), and ≥6 months since last prior treatment (P = 0·032). Overall, lenalidomide improved PFS versus single-agent IC therapy in patients with relapsed/refractory MCL, irrespective of many demographic factors, disease characteristics and prior treatment history
- …